Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia.

ABSTRACT: The advent of chimeric antigen receptor (CAR) T-cell therapy has led to dramatic remission rates in multiple relapsed/refractory hematologic malignancies. While CAR T-cell therapy has been particularly successful as a treatment for B-cell malignancies, effectively treating acute myeloid leukemia (AML) with CARs has posed a larger challenge. AML not only creates an immunosuppressive tumor microenvironment that dampens CAR T-cell responses, but it also lacks many unique tumor-associated antigens, making leukemic-specific targeting difficult. One advantage of CAR T-cell therapy compared to alternative treatment options is the ability to provide prolonged antigen-specific immune effector and surveillance functions. Since many AML CAR targets under investigation including CD33, CD117, and CD123

SUBMITTER: Marvin-Peek J 

PROVIDER: S-EPMC8833567 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature